预约演示

1.58亿美元助力，潜在“first-in-class”ADC即将展开关键临床试验

2024-04-11

投融资

抗体药物偶联物临床1期临床2期

TORL BioTherapeutics今日宣布完成了超额的1.58亿美元B2轮融资，获得的资金将用于推动该公司研发管线中的多款潜在“first-in-class”和“best-in-class”抗体偶联药物（ADC）的临床开发。

本轮融资由Deep Track Capital领投，包括RA Capital Management、Perceptive Advisors 和Avidity Partners在内的新生物技术投资者加入。包括Goldman Sachs Alternatives、UC Investments、百时美施贵宝、Vertex Ventures、Moore Strategic Ventures、Blue Owl Healthcare Opportunities和Perceptive Xontogeny Venture Fund在内的现有投资者也参与了融资。

该公司的主打在研疗法TORL-1-23是一款靶向CLDN 6的潜在“first-in-class”ADC，目前正在1期临床试验中接受评估，预计在今年下半年启动2期临床试验。这一临床试验旨在支持TORL-1-23的监管审评和潜在批准，用于治疗CLDN 6阳性，对含铂化疗耐药的卵巢癌。

此外，获得资金还将用于支持TORL-2-307正CLDN 6临床试验，它是一款靶向CLDN 18.2的单克隆抗体和ADC。该公司的研发管线中还包括治疗CDH17阳性结直肠癌的ADC疗法TORL-3-600和治疗DLK1阳性肿瘤的ADC疗法TORL-4-500。含铂化疗耐药的卵巢癌

Mark J. Alles先生是TORL BioTherapeutics的首席执行官。此前他是Celgene公司的董事长兼首席执行官，在生物医药领域拥CDH17阳性结直肠癌在多家专注于TORL-3-600推动创DLK1方面拥有杰出的记录。TORL-4-500

参考资料：Celgene

[1] TORL BioTherapeutics Announces $158 Million Oversubscribed Series B-2 Financing to Advance the Clinical Development of its Novel Antibody-Drug Conjugate (ADC) Oncology Pipeline. Retrieved April 10, 2024, from https://www.prnewswire.com/news-releases/torl-biotherapeutics-announces-158-million-oversubscribed-series-b-2-financing-to-advance-the-clinical-development-of-its-novel-antibody-drug-conjugate-adc-oncology-pipeline-302112553.html

[2] TORL BioTherapeutics Announces Appointment of Mark J. Alles as Chairman and Chief Executive Officer; Highlights Significant Progress of its Oncology Clinical Programs. Retrieved April 10, 2024, from https://www.prnewswire.com/news-releases/torl-biotherapeutics-announces-appointment-of-mark-j-alles-as-chairman-and-chief-executive-officer-highlights-significant-progress-of-its-oncology-clinical-programs-302029058.html

内容来源于网络，如有侵权，请联系删除。

机构